Possible protective effects of the agonist [D-TrpV]LH-RH (the D-tryptophan-6 analog of luteinizing hormone-releasing hormone) against testicular damage caused by cyclophosphamide (Cytoxan) were investigated in subhuman primates. Three adult male baboons (Papio anubis) were first subjected to normal semen evaluation by using electroejaculation. There may be differences in the sensitivity of the prepubertal, pubertal, and adult testis to chemotherapy with alkylating agents (1-3, 8) . The prepubertal testis may be more resistant to the effects of alkylating agents than is the adult gonad (2). Prepubertal boys and boys in early puberty treated with cyclophosphamide for nephrosis appear to have normal follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels after therapy as well as normal levels of testosterone. These effects seem to be also dependent on the dosage and duration of therapy (1, 3, 8) . In one study cyclophosphamide, which was used for chemotherapy in a dose of 50-100 mg daily in adult males for 4 months, induced azoospermia (3). In another study with cyclophosphamide in children with nephrosis, results showed two distinct patterns. Four males who received 2-4 mg/kg of body weight per day for 49-60 days had normal semen, while four patients who received 2-5 mg/kg per day for 89-489 days showed azoospermia.
continued to receive this agonist until 1 week after the last dose of Cytoxan. In one of the two baboons treated with Cytoxan and the LH-RH agonist, the white blood count fell below 4000 per ,jl, and the dose of Cytoxan had to be reduced to 1.5 mg/kg per day for 12 days. The control animal developed azoospermia after 4 months of treatment with cyclophosphamide, and serum testosterone increased while sperm count decreased. Four weeks after the agonist was stopped, serum testosterone in both animals pretreated with [D-Trp6JLH-RH returned to normal levels. The control animal showed a small amount of nonmotile sperm 2.5 months after cessation of treatment, but after 9 months remains oligospermic with poor sperm motility. In one of the animals treated with LH-RH agonist, semen analysis returned to normal pretreatment values 8 months after withdrawal of treatment. The other animal remains oligospermic 10 months after therapy, but the motility is improving. These preliminary results suggest that treatment with LH-RH agonist might decrease the gonadal damage caused by some chemotherapeutic agents.
Chemotherapeutic agents have produced beneficial results in the therapy of carcinomas, particularly in some blood and lymph node malignancies, but side effects of these agents can be quite severe. One of these side effects is gonadal suppression leading to oligospermia or azoospermia (1) (2) (3) (4) (5) (6) (7) (8) . Under some conditions azoospermia appears to be permanent and results in sterility. Cyclophosphamide, a cyclic nitrogen mustard phosphamide ester and an alkylating agent, has been used for cancer chemotherapy and treatment of the nephrotic syndrome, particularly in childhood. Oligospermia and azoospermia have been reported after the use of this agent (2, 3, (6) (7) (8) .
There may be differences in the sensitivity of the prepubertal, pubertal, and adult testis to chemotherapy with alkylating agents (1) (2) (3) 8) . The prepubertal testis may be more resistant to the effects of alkylating agents than is the adult gonad (2) . Prepubertal boys and boys in early puberty treated with cyclophosphamide for nephrosis appear to have normal follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels after therapy as well as normal levels of testosterone. These effects seem to be also dependent on the dosage and duration of therapy (1, 3, 8) . In one study cyclophosphamide, which was used for chemotherapy in a dose of 50-100 mg daily in adult males for 4 months, induced azoospermia (3). In another study with cyclophosphamide in children with nephrosis, results showed two distinct patterns. Four males who received 2-4 mg/kg of body weight per day for 49-60 days had normal semen, while four patients who received 2-5 mg/kg per day for 89-489 days showed azoospermia.
LH-releasing hormone (LH-RH) agonists and antagonists effectively but reversibly inhibit the pituitary-gonadal function and fertility in animals (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Chronic administration of superactive agonists of LH-RH produces dramatic inhibitory effects through a process of down-regulation of receptors, desensitization of pituitary gonadotrophs, and suppression of gonads (9) (10) (11) (12) (13) (14) (15) 20) . In male animals this is manifested by a decrease in the weights of testes, seminal vesicles, and prostate; inhibition of spermatogenesis; and a decrease in plasma LH, FSH, and testosterone levels (9-11, 13, 15, 21-27 (9-11, 16, 21, 22, 28, 29) . The inhibition of reproductive functions in animals and human beings of both sexes by agonists of LH-RH is reversible and fertility is restored after treatment is stopped (9-11, 14, 16, 19, 21, 22, 30) .
Dividing cells are more sensitive to alkylating agents than are resting cells (2, 11 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. agent was started, during the chemotherapy, and for 1 week after it would suppress testicular function and maintain inactive gonads. Consequently, chemotherapy might damage the testes temporarily inhibited by LH-RH analogs to a lesser extent than in the case of the unsuppressed gonads.
Recently Glode et al. (31) reported that temporary inhibition of the pituitary-gonadal axis by administration of [DLeu6]LH-RH ethylamide protected mouse testes from cyclophosphamide-induced damage (31) . However, these conclusions were based on only two treated mice (31) , and more experimental work is needed to confirm and extend these initial findings.
METHODS
Three adult male baboons (Papio anubis) were used in the study. Baseline complete blood count (CBC) and serum testosterone levels were determined, and three semen analyses were obtained by rectal probe ejaculation after ketamine injection (1 mg/kg).
After baseline studies, two animals were given daily subcutaneous injections of 0.5 mg (approximately 22 Figs. 1 and 2) . Testosterone showed an initial rise 24 hr after the LH-RH agonist was started, but after 1 week the testosterone levels began to fall, and after 1 month the values were only 0.33 and 0.28 ng/ml. Serum testosterone remained in this range throughout the cyclophosphamide-treatment period. Serum testosterone showed no change 2 weeks after therapy, but by 4 weeks the level of testosterone for both animals was back to baseline.
These two animals received a total dose of approximately 106 mg of the LH-RH agonist, 48 mg being administered prior to cyclophosphamide treatment. The animals 7594 and D386 and the control baboon E028 were treated with cyclophosphamide for 4 months. One of the animals treated with the LH-RH agonist (7594) and the control (E028) tolerated the full experimental dose of cyclophosphamide without incident, receiving 2.9 and 2.7 mg/kg per day for a total of 7 and 7.5 g, respectively. However, in one of the analog-treated animals (D386), the leukocyte count decreased to less than 4000 per 41 on several occasions. This z~~~~1 0.0 E . i0/ animal received only 4 g (2.01 mg/kg per day) of cyclophosphamide, the drug being withheld for a total of 12 days during the 4-month period of treatment.
The control animal (E028) showed essentially no changes in the sperm count 1 month after the treatment with Cytoxan was started. However, with each successive month of therapy with Cytoxan, the sperm count declined, and at 4 months, when cyclophosphamide was stopped, the animal was azoospermic. The serum testosterone level increased as the sperm count decreased (Fig. 3) . Semen analyses for the two LH-RH agonist-treated animals showed azoospermia until 7 months elapsed after withdrawal of treatment. At that time both animals had a minimal number of poorly motile sperm. Eight months after cessation of treatment, the sperm count in one of the animals became completely normal (588 x 106 sperm per ml; 85% motile; grade 4/4). The other baboon remains oligospermic (7.4 x 106 sperm per ml) 10 months after treatment, but the motility has increased to 40% of a grade 3/4. The control animal showed a small amount of nonmotile sperm 2.5 months after cyclophosphamide was stopped, but 9 months after cessation of treatment, it still remains oligospermic (4.75 x 106 sperm per ml) with poorly motile sperm (Figs. 1-3) .
Testicular biopsies were normal in one of the LH-RH agonist-treated animals that had normal semen analyses except for rare hypospermatogenic tubules. The other agonisttreated animal, which has remained oligospermic, shows approximately one-third of the tubules with moderate-to- Trp6]LH-RH is oligospermic 10 months after both agents were stopped, but the motility is improving, and there has been a steady increase in sperm concentration. In this animal bone marrow was affected by cyclophosphamide because the leukocyte count declined to less than 4000 per gl. This may indicate increased sensitivity of this particular animal to cyclophosphamide, accounting for greater testicular damage. It should be noted that sperm were not found in either of these animals until the month 7 after withdrawal of treatment with the agonist. This period is somewhat longer than has been reported previously for the subhuman primates (27, 32) . However, our doses of agonist were higher and the duration of treatment was more extended than in those studies (27, 32) . The control animal developed sperm in the ejaculate 2.5 months after cyclophosphamide was stopped but remains oligospermic after 9 months, and the sperm has shown poor motility. An interesting observation in the two animals treated with the LH-RH agonist was an initial increase in sperm concentration. This factor should be further investigated in the subhuman primate model as a possible treatment for oligospermia in infertility. 
